Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

#411

Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.

Aim(s): We evaluated the efficacy and safety profile of 177Lu-PRRT administered at two different dosages (500 mCi and 750 mCi).

Materials and methods: Fifty-two patients received a cumulative activity of 18.5 – 27.8 GBq in five cycles, administered on the basis of kidney function or bone marrow reserve.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O,

Keywords: neuroendocrine, peptide receptor radionuclide therapy,